Abstract
The NF-kappaB family of transcription factors functions broadly in the host control of immunoregulatory gene expression, inflammation, and apoptosis. Using Jurkat T cells engineered to inducibly express a transdominant repressor of IkappaBalpha, we examined the role of NF-kappaB in the regulation of cytokine and apoptotic gene expression. In this T cell model, as well as in primary T lymphocytes, expression of TNF-related apoptosis-inducing ligand (TRAIL) apoptotic signaling protein was dramatically down-regulated by inhibition of NF-kappaB binding activity. TRAIL acts through membrane death receptors to induce apoptosis of activated T lymphocytes and can be up-regulated by a variety of physiological and pharmacological inducers. However, regulation of TRAIL gene expression has not been defined. Treatment with TCR mimetics (PMA/ionomycin, PHA, and anti-CD3/CD28 Abs) resulted in a rapid increase in the expression of TRAIL mRNA and cell surface TRAIL protein. Induction of the transdominant repressor of IkappaBalpha dramatically down-regulated surface expression of TRAIL, indicating an essential role for NF-kappaB in the regulation of TRAIL. The induced expression of TRAIL was linked to a c-Rel binding site in the proximal TRAIL promoter at position -256 to -265; mutation of this site or an adjacent kappaB site resulted in a complete loss of the inducibility of the TRAIL promoter. The regulation of TRAIL expression by NF-kappaB may represent a general mechanism that contributes to the control of TRAIL-mediated apoptosis in T lymphocytes.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Substitution
-
Antibodies, Monoclonal / pharmacology
-
Apoptosis / drug effects*
-
Apoptosis / genetics
-
Apoptosis Regulatory Proteins
-
CD28 Antigens / immunology
-
CD3 Complex / immunology
-
DNA-Binding Proteins / chemistry
-
DNA-Binding Proteins / genetics
-
DNA-Binding Proteins / physiology*
-
Gene Expression Regulation / drug effects*
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
I-kappa B Proteins*
-
Ionomycin / pharmacology
-
Jurkat Cells
-
Membrane Glycoproteins / biosynthesis*
-
Membrane Glycoproteins / genetics
-
Mutagenesis, Site-Directed
-
NF-KappaB Inhibitor alpha
-
NF-kappa B / antagonists & inhibitors
-
NF-kappa B / physiology*
-
Neoplasm Proteins / biosynthesis
-
Neoplasm Proteins / genetics
-
Phytohemagglutinins / pharmacology
-
Promoter Regions, Genetic
-
Proto-Oncogene Proteins c-rel / metabolism
-
RNA, Messenger / biosynthesis
-
RNA, Messenger / genetics
-
RNA, Neoplasm / biosynthesis
-
RNA, Neoplasm / genetics
-
Recombinant Fusion Proteins / physiology
-
T-Lymphocytes / drug effects*
-
T-Lymphocytes / metabolism
-
TNF-Related Apoptosis-Inducing Ligand
-
Tetradecanoylphorbol Acetate / pharmacology
-
Transcription, Genetic / drug effects*
-
Transfection
-
Tumor Necrosis Factor-alpha / biosynthesis*
-
Tumor Necrosis Factor-alpha / genetics
-
Tumor Necrosis Factor-alpha / physiology
Substances
-
Antibodies, Monoclonal
-
Apoptosis Regulatory Proteins
-
CD28 Antigens
-
CD3 Complex
-
DNA-Binding Proteins
-
I-kappa B Proteins
-
Membrane Glycoproteins
-
NF-kappa B
-
NFKBIA protein, human
-
Neoplasm Proteins
-
Phytohemagglutinins
-
Proto-Oncogene Proteins c-rel
-
RNA, Messenger
-
RNA, Neoplasm
-
Recombinant Fusion Proteins
-
TNF-Related Apoptosis-Inducing Ligand
-
TNFSF10 protein, human
-
Tumor Necrosis Factor-alpha
-
NF-KappaB Inhibitor alpha
-
Ionomycin
-
Tetradecanoylphorbol Acetate